Pharmaceutical Research Center, Mochida Pharmaceutical Co., Ltd., 722 Jimba-aza-Uenohara, Gotemba, Shizuoka 412-8524, Japan.
Steroids. 2011 Jan;76(1-2):60-7. doi: 10.1016/j.steroids.2010.08.010. Epub 2010 Sep 21.
Prostaglandin E(2) (PGE(2)) is a major mediator in the pathophysiology, and pathogenesis of gynecological diseases associated with abnormal endometrial disease with proliferation and inflammation, such as endometriosis. In this study, we investigated the effect of dienogest, a selective progesterone receptor agonist, on PGE(2) production and the expression of aromatase, an estrogen synthase, in human immortalized endometrial epithelial cells. Compared with monolayer culture, the cells showed enhanced PGE(2) production and expression of the PGE(2) synthases cyclooxygenase-2 (COX-2), and microsomal prostaglandin E(2) synthase-1 (mPGES-1) in a spheroid culture system. Dienogest inhibited PGE(2) production and this effect was reversed by RU486, a progesterone receptor antagonist. Dienogest inhibited the PGE(2) synthases mRNA and protein expression, and the nuclear factor-κB activation. Moreover, the suppressive effect of dienogest on PGE(2) production was sustained 24h after the drug was withdrawn. Dienogest but not COX inhibitors inhibited aromatase expression. These results suggest that progesterone receptor activation reduces the gene expressions of COX-2, mPGES-1, and aromatase. Our findings suggest that the pharmacological mechanism of dienogest includes the direct inhibition of PGE(2) synthase and aromatase expression and may contribute to the therapeutic effect on the progression of endometriosis.
前列腺素 E(2)(PGE(2))是与子宫内膜疾病异常增生和炎症相关的妇科疾病的病理生理学和发病机制中的主要介质,例如子宫内膜异位症。在这项研究中,我们研究了选择性孕激素受体激动剂地诺孕素对人永生化子宫内膜上皮细胞中 PGE(2)产生和芳香酶(雌激素合成酶)表达的影响。与单层培养相比,在球体培养系统中,细胞表现出增强的 PGE(2)产生和 PGE(2)合成酶环氧化酶-2(COX-2)和微粒体前列腺素 E(2)合成酶-1(mPGES-1)的表达。地诺孕素抑制 PGE(2)的产生,而孕激素受体拮抗剂 RU486 可逆转这种作用。地诺孕素抑制 PGE(2)合成酶的 mRNA 和蛋白表达以及核因子-κB 的激活。此外,停药 24 小时后,地诺孕素对 PGE(2)产生的抑制作用仍持续存在。地诺孕素而非 COX 抑制剂抑制芳香酶的表达。这些结果表明,孕激素受体激活可降低 COX-2、mPGES-1 和芳香酶的基因表达。我们的研究结果表明,地诺孕素的药理机制包括直接抑制 PGE(2)合成酶和芳香酶的表达,这可能有助于治疗子宫内膜异位症的进展。